The epidemiology of herpes zoster in immunocompetent, unvaccinated adults ≥50 years old: incidence, complications, hospitalization, mortality, and recurrence.
Data on the epidemiology of herpes zoster (HZ), particularly in the unvaccinated, immunocompetent population, are needed to assess disease burden and the potential impact of vaccination. Conducted at Kaiser Permanente Southern California, a large integrated healthcare organization, the study comprised five elements: (1) Incidence estimated from immunocompetent adults ≥50 years unvaccinated with zoster vaccine live who had incident HZ in 2011-2015; (2) The proportion of HZ-related non-pain complications assessed by double abstraction of electronic health records (EHRs) of 600 incident patients from 2011-2015; (3) HZ-related hospitalizations identified among HZ patients diagnosed in 2015; (4) HZ-related death determined from automated data and review of EHRs; (5) Recurrent HZ identified from a cohort initially diagnosed with HZ in 2007-2008 and followed through 2016. The HZ incidence rate was 9.92/1,000 person-years (95% confidence interval [CI]:9.82-10.01). The proportion of cutaneous, neurologic, and other complications was 6.40% (95% CI:1.73-11.07%), 0.77% (95% CI:0.00-2.36%), and 1.01% (95% CI:0.00-2.93%), respectively. Only 0.86% of patients had a HZ-related hospitalization. The case-fatality rate was 0.04%. The recurrence rate was 10.96/1,000 person-years (95% CI:10.18-11.79) with a 10-year recurrence risk of 10.26% (95% CI:9.36-11.23%). These recent HZ epidemiology data among an immunocompetent, unvaccinated population measure real-world disease burden.